Previous 10 | Next 10 |
Collaboration employing Guardant360 CDx assay is first to use ctDNA comprehensive genomic profiling blood test for early detection of resistance due to ESR1 mutation prior to first-line therapy progression Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, ann...
Presentations to highlight role of Guardant liquid biopsy tests and real-world data to help identify actionable biomarkers, co-occurring mutations and molecular response to therapy Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new dat...
Summary CareDx reported lackluster performance in the third quarter, with core testing revenue down by 2.5%, mirroring intensifying competitive dynamics impacting its pricing power. Competitive dynamics are exacerbated by the company's expansion in niche markets with structurally ...
Summary GH's aberrant trading pattern after its Q3 earnings release on Friday mirrors two conflicting trends arising from the company's unique market position. A new paradigm in the gene testing market is now emphasizing clearer paths to profitability, contradicting GH's spending ...
Guardant Health, Inc. (GH) Q3 2022 Earnings Conference Call November 03, 2022 04:30 PM ET Company Participants Alex Kleban - Vice President, Investor Relations Helmy Eltoukhy - Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Mike Bell ...
The following slide deck was published by Guardant Health, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Guardant Health, Inc. 2022 Q3 - Results - Earnings Call Presentation
Guardant Health press release ( NASDAQ: GH ): Q3 Non-GAAP EPS of -$1.18 misses by $0.10 . Revenue of $117.4M (+23.9% Y/Y) misses by $0.5M . Adjusted EBITDA loss was $112.8M for the third quarter of 2022, as compared to a $65.2M loss for the corresponding prior ...
Q3 clinical and biopharma volumes up 42% and 40% year over year Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported fin...
Summary The FDA is preparing to extend its regulatory arm over LDTs. The potential for negative regulatory intervention puts OCX's strategy into serious question. OCX must navigate the new regulations and the limited resources that come with being a small-cap company while try...
There's big news for Guardant Health (NASDAQ: GH) shareholders today -- but disappointing news also. This morning, analysts at investment bank Craig-Hallum announced a switch in their bets on cancer-screening biopsy companies, downgrading shares of Exact Sciences (NASDAQ: ...
News, Short Squeeze, Breakout and More Instantly...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...
2024-07-21 23:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...